Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

Inclusion Criteria:

* Previously untreated, histological documented stage IIIB (not amenable for radical regional therapy) or stage IV squamous cell carcinoma of lung. At least one measurable lesion as defined by RECIST criteria.
* At least 18 years of age.
* ECOG PS 0\~1
* Patients have no previously malignant tumor history except cured cervical carcinoma in situ, basal cell carcinoma or superficial bladder cancer. Patients are also eligible if they have received a chemotherapy regimen as neoadjuvant or adjuvant chemotherapy and the disease recurred over 12 months since the finishing of neoadjuvant or adjuvant chemotherapy.
* neutrophil ≥ 1.5 x 109 /L, Hemoglobin \> 90 g/L, Platelet count \> 100x109/L.
* Total bilirubin ≤ 1.5 x upper limit of normal. ALT and AST \< 2.5 x upper limit of normal without liver metastasis, ALT and AST \< 5 x upper limit of normal with liver metastasis. Serum creatinine \< 1.5 x upper limit of normal.
* Urine pregnancy test is negative for woman.
* Estimated life expectancy is at least 3 months.
* Patient comply with the clinical trial protocal.
* Informed consent must be signed.

Exclusion Criteria:

* Patients who are currently undergoing other anti-tumor therapy.
* Patients who was enrolled in any other clinical trial within 4 weeks of study entry.
* Any physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any study medication or render the subject at high risk from treatment.
* Central nervous system (CNS) tumor or metastatic tumor.
* Serious mental disorder.
* Serious dysgnosia.
* Other serious comorbidity.
* Alcohol or drug dependence.
* Previously allergic to drugs used in the study.